Form 4: Repare Therapeutics EVP, CFO Steve Forte Reports Stock Option Grant and RSU Award
SEC Form 4
Steve Forte, EVP and CFO of Repare Therapeutics, reports the acquisition of stock options and a restricted stock unit award, along with adjustments to his holdings of common shares.
Summary
- On March 4, 2025, Steve Forte, the EVP and CFO of Repare Therapeutics, reported transactions involving the company's securities.
- Forte acquired 14,000 shares through a restricted stock unit (RSU) award, which will vest in three equal installments on March 4, 2026, March 4, 2027, and March 4, 2028, contingent upon continued service.
- He also acquired options to purchase 200,000 shares at an exercise price of $1.17, vesting fully on March 4, 2026, subject to continued service.
- Additionally, Forte acquired options to purchase 85,000 shares at an exercise price of $1.17, with 25% vesting on March 4, 2026, and the remaining shares vesting monthly thereafter, also subject to continued service.
- Forte's total holdings include 61,670 common shares, incorporating shares acquired through the employee stock purchase plan on August 15, 2024 (895 shares) and February 15, 2025 (2,000 shares).
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, indicating a stable and incentivized management structure. The sentiment is neutral to positive.
Positives
- The granting of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
- The vesting schedules of the RSUs and stock options incentivize continued service and commitment from the CFO.
Risks
- The value of the stock options and RSUs is dependent on the future performance of Repare Therapeutics' stock.
- If Forte leaves the company before the vesting dates, he may forfeit unvested RSUs and stock options.
Future Outlook
The document outlines future vesting dates for the granted RSUs and stock options, contingent upon the reporting person's continued service.
Industry Context
Stock option and RSU grants are common practices in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants and RSU awards are standard compensation practices in the biotech industry, often used to align executive incentives with shareholder value.
- Comparable companies like Relay Therapeutics or Black Diamond Therapeutics also utilize equity-based compensation as part of their executive compensation packages.
- The vesting schedules described are typical, with vesting periods ranging from one to three years, contingent on continued employment.
Stakeholder Impact
- Shareholders may view the stock option and RSU grants positively, as they align management's interests with the company's long-term success.
- Employees may be motivated by the knowledge that executives are incentivized to improve the company's performance.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | 895 shares acquired under the Issuer's employee stock purchase plan. |
| 02/15/2025 | 2,000 shares acquired under the Issuer's employee stock purchase plan. |
| 03/04/2025 | Date of transaction: RSU award and stock option grants. |
| 03/04/2026 | First vesting date for RSUs (33 1/3%) and 25% of the 85,000 stock options; full vesting of 200,000 stock options. |
| 03/04/2027 | Second vesting date for RSUs (33 1/3%). |
| 03/04/2028 | Final vesting date for RSUs (33 1/3%). |
| 03/03/2035 | Expiration date for the stock options. |
| 03/06/2025 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.